论文部分内容阅读
目的:探讨NK-1受体拮抗剂对子宫内膜癌Ishikawa细胞增殖、凋亡、细胞周期及侵袭影响。方法:体外培养子宫内膜腺癌Ishikawa细胞,将不同浓度NK-1受体拮抗剂与其共培养48h后,采用MTT法检测Ishikawa细胞增殖情况;采用流式细胞术检测细胞凋亡率及细胞周期分布;利用Transwell实验检测细胞侵袭能力。结果:NK-1受体拮抗剂可明显抑制Ishikawa细胞增殖(P<0.05);促进细胞凋亡,使细胞周期中G0/G1期比例增加,S期及G2/M期比例降低(P均<0.05);抑制细胞侵袭,并且其对Ishikawa细胞的这些作用均呈剂量依赖性。结论:NK-1受体拮抗剂可明显抑制子宫内膜癌细胞增殖、阻滞细胞周期、诱导凋亡及抑制侵袭,有望成为子宫内膜细胞治疗的新途径。
Objective: To investigate the effects of NK-1 receptor antagonist on proliferation, apoptosis, cell cycle and invasion of Ishikawa cells in endometrial carcinoma. Methods: Ishikawa cells of endometrial adenocarcinoma were cultured in vitro. After co-cultured with different concentrations of NK-1 receptor antagonist for 48 hours, the proliferation of Ishikawa cells was detected by MTT assay. The apoptosis rate and cell cycle were detected by flow cytometry Distribution; Transwell assay was used to detect cell invasion ability. Results: NK-1 receptor antagonist could significantly inhibit the proliferation of Ishikawa cells (P <0.05), promote cell apoptosis, increase the proportion of G0 / G1 phase and decrease the proportion of S phase and G2 / M phase in the cell cycle (P < 0.05); inhibit cell invasion, and its effect on Ishikawa cells in a dose-dependent manner. Conclusion: NK-1 receptor antagonist can significantly inhibit the proliferation of endometrial cancer cells, arrest the cell cycle, induce apoptosis and inhibit the invasion, which is expected to become a new way of endometrial cell therapy.